论文部分内容阅读
目的探讨分析瑞格列奈联合罗格列酮治疗糖尿病的临床疗效。方法选取82例2型糖尿病患者,将其随机分为观察组和对照组,分别给予瑞格列奈联合罗格列酮治疗和单纯瑞格列奈治疗,比较两组患者临床疗效,治疗前后空腹血糖、餐后2 h血糖、糖化血红蛋白、三酰甘油及胆固醇水平,同时观察患者治疗过程中的不良反应发生率。结果观察组临床疗效总有效率为95.12%,较对照组(80.49%)显著提高,治疗后观察组空腹血糖、餐后2 h血糖、糖化血红蛋白、三酰甘油及胆固醇水平较对照组显著下降;观察组不良反应发生率为7.32%,显著低于对照组的24.39%,差异有统计学意义(P<0.05)。结论瑞格列奈联合罗格列酮治疗2型糖尿病患者可显著提高临床疗效,尤其是改善患者临床症状疗效显著,空腹血糖、餐后2 h血糖、糖化血红蛋白、三酰甘油及胆固醇水平均显著改善,且降低不良反应发生情况,值得进一步在临床上推广。
Objective To investigate the clinical efficacy of repaglinide in combination with rosiglitazone in the treatment of diabetes mellitus. Methods 82 patients with type 2 diabetes mellitus were randomly divided into observation group and control group. The patients were treated with repaglinide and rosiglitazone respectively and repaglinide alone. The clinical effects of the two groups were compared before and after treatment Blood glucose, 2 h postprandial blood glucose, glycosylated hemoglobin, triglyceride and cholesterol levels, while observing the incidence of adverse reactions in patients with treatment. Results The total effective rate of observation group was 95.12%, which was significantly higher than that of control group (80.49%). After treatment, fasting blood glucose, postprandial 2h blood glucose, glycosylated hemoglobin, triglyceride and cholesterol were significantly lower than those in control group. The incidence of adverse reactions in the observation group was 7.32%, which was significantly lower than that in the control group (24.39%), the difference was statistically significant (P <0.05). Conclusion The combination of repaglinide and rosiglitazone in type 2 diabetic patients can significantly improve the clinical efficacy, especially in improving clinical symptoms. The fasting blood glucose, 2 h postprandial blood glucose, glycosylated hemoglobin, triglyceride and cholesterol levels were significantly higher Improve, and reduce the incidence of adverse reactions, it is worth further clinical promotion.